Performance of immunochemical fecal occult blood tests among users of low-dose aspirin

JAMA

Volumn 305, Issue 11, 2011, Pages 1093-

  Chan, Yap Hang ^a   Schooling, C Mary ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

CANCER RISK; CANCER SCREENING; CANCER STAGING; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; HUMAN; IMMUNOCHEMICAL FECAL OCCULT BLOOD TEST; LETTER; LOW DRUG DOSE; OCCULT BLOOD TEST; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; TUMOR BLEEDING;

EID: 79952583143     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.297     Document Type: Letter

References (3)

1. Brenner H, Tao S, Haug U. Low-dose aspirin use and performance of immunochemical fecal occult blood tests. JAMA. 2010;304(22):2513-2520.
2. Chan AO, Jim MH, Lam KF, et al. Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. JAMA. 2007;298(12): 1412-1419. (Pubitemid 47481607)
3. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741-1750.